Regeneron: The Mouse That Saved the World

Discover how a failed neurology startup used a genetically engineered mouse to build a multi-billion dollar biotech empire and fight COVID-19.[INTRO]ALEX: In October 2020, at the height of the COVID-19 pandemic, a helicopter rushed the President of the United States to Walter Reed Medical Center for an experimental drug that hadn't even been FDA-approved yet.JORDAN: I remember that — the antibody cocktail. People were calling it a miracle cure before the clinical trials were even finished.ALEX: That drug came from Regeneron, a company that started with a $1 million investment and a dream of regrowing brain cells, only to fail completely at its original mission before becoming one of the most powerful biotech forces on Earth.JORDAN: So they failed their way to the top? That sounds like a story worth digging into.[CHAPTER 1 - Origin]ALEX: It starts in 1988 with two men: Dr. Leonard Schleifer, a neurologist, and George Yancopoulos, a brilliant young biologist. They wanted to do something that sounded like science fiction — regenerating neurons to cure diseases like ALS.JORDAN: Hence the name "Regeneron." It’s literally "Regenerating Neurons."ALEX: Exactly. They were the ultimate "science-first" duo. Schleifer was the business visionary who convinced Amgen to invest, and Yancopoulos was the scientific engine. But for the first twenty years, they were basically a professional heartbreak machine.JORDAN: Wait, twenty years? Most startups would have burned through their cash and folded in five.ALEX: That’s the wild part. They spent the 90s chasing neurological drugs that failed one after another in clinical trials. But instead of quitting, they used that time to build something better than a single drug — they built a factory for making drugs.JORDAN: A factory? Like a manufacturing plant?ALEX: No, a genetic platform. They developed the "VelocImmune" mouse. They essentially replaced a mouse’s immune system with human genes so that when the mouse was exposed to a disease, it would produce fully human antibodies that could be turned into medicine.[CHAPTER 2 - Core Story]ALEX: By the mid-2000s, Regeneron stopped trying to fix brains and started using their "Trap" technology to fix eyes. In 2011, the FDA approved EYLEA for wet macular degeneration.JORDAN: Was it a big deal? There are plenty of eye drops out there.ALEX: This wasn't an eye drop; it was an injection that stopped people from going blind. It was more effective and required fewer shots than its competitors. It became a multi-billion dollar “mega-blockbuster” almost overnight.JORDAN: So they finally had their hit. But how do you go from eye injections to treating the President for a respiratory virus?ALEX: That’s where the VelocImmune mouse comes back. Because they had this repeatable "engine," they could pivot to any disease. They partnered with Sanofi and churned out Dupixent for eczema and Praluent for cholesterol.JORDAN: They were basically printing medications at that point.ALEX: They were. And when COVID-19 hit in 2020, they moved faster than anyone thought possible. Within months, Yancopoulos’s team identified the best antibodies and created REGEN-COV. It was the fastest drug development in history, and it worked—at least until the virus mutated.JORDAN: Right, I heard it stopped working against Omicron. What happened then?ALEX: The FDA pulled the emergency use authorization in 2022. It was a brutal reminder that in biotech, the virus always gets a vote. But by then, Regeneron was already a household name with yearly revenues topping $12 billion.[CHAPTER 3 - Why It Matters]JORDAN: So, they’re massive now. But besides the COVID fame, why does Regeneron matter to the average person today?ALEX: Because they are changing how we find drugs in the first place. Their Genetics Center has sequenced over one million human genomes. They aren't just guessing which proteins to target; they’re using massive data sets to find the genetic "on-off" switches for disease.JORDAN: That sounds expensive. I'm guessing these drugs don't come cheap.ALEX: That’s the big controversy. They’ve been grilled by Congress over pricing — EYLEA can cost $1,850 per injection, and Dupixent is over $30,000 a year. It’s the classic biotech paradox: life-saving innovation versus extreme costs.JORDAN: And the founders? Are they still running the show?ALEX: They are. Schleifer and Yancopoulos have been together for over 35 years. In an industry where CEOs swap out every few years, their partnership is the longest-running bromance in biotech history.[OUTRO]JORDAN: All right, give it to me straight. What’s the one thing to remember about Regeneron?ALEX: Regeneron proved that if you build the right genetic technology platform, you can pivot from failing at brain science to saving the world from a pandemic in record time.JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai